Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Primary progressive narcolepsy type 1: the other side of the coin.

Literature DB >> 25355832

Primary progressive narcolepsy type 1: the other side of the coin.

Fabio Pizza¹, Stefano Vandi¹, Rocco Liguori¹, Piero Parchi¹, Patrizia Avoni¹, Emmanuel Mignot¹, Giuseppe Plazzi².

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2014 PMID： 25355832 PMCID： PMC4276406 DOI： 10.1212/WNL.0000000000001051

Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910

× No keyword cloud information.

6 in total

Review 1. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination.

Authors: Markku Partinen; Birgitte Rahbek Kornum; Giuseppe Plazzi; Poul Jennum; Ilkka Julkunen; Outi Vaarala
Journal: Lancet Neurol Date: 2014-06 Impact factor: 44.182

2. Daytime continuous polysomnography predicts MSLT results in hypersomnias of central origin.

Authors: Fabio Pizza; Keivan K Moghadam; Stefano Vandi; Stefania Detto; Francesca Poli; Emmanuel Mignot; Raffaele Ferri; Giuseppe Plazzi
Journal: J Sleep Res Date: 2012-06-20 Impact factor: 3.981

3. Hypocretin deficiency develops during onset of human narcolepsy with cataplexy.

Authors: Andri Savvidou; Stine Knudsen; Mia Olsson-Engman; Steen Gammeltoft; Poul Jennum; Lars Palm
Journal: Sleep Date: 2013-01-01 Impact factor: 5.849

4. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy.

Authors: Olivier Andlauer; Hyatt Moore; Seung-Chul Hong; Yves Dauvilliers; Takashi Kanbayashi; Seiji Nishino; Fang Han; Michael H Silber; Tom Rico; Mali Einen; Birgitte R Kornum; Poul Jennum; Stine Knudsen; Sona Nevsimalova; Francesca Poli; Giuseppe Plazzi; Emmanuel Mignot
Journal: Sleep Date: 2012-09-01 Impact factor: 5.849

5. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy.

Authors: Thomas C Thannickal; Robert Nienhuis; Jerome M Siegel
Journal: Sleep Date: 2009-08 Impact factor: 5.849

6. Reduced number of hypocretin neurons in human narcolepsy.

Authors: T C Thannickal; R Y Moore; R Nienhuis; L Ramanathan; S Gulyani; M Aldrich; M Cornford; J M Siegel
Journal: Neuron Date: 2000-09 Impact factor: 17.173

6 in total

13 in total

Review 1. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.

Authors: Steven T Szabo; Michael J Thorpy; Geert Mayer; John H Peever; Thomas S Kilduff
Journal: Sleep Med Rev Date: 2018-11-08 Impact factor: 11.609

2. Nocturnal Sleep Dynamics Identify Narcolepsy Type 1.

Authors: Fabio Pizza; Stefano Vandi; Martina Iloti; Christian Franceschini; Rocco Liguori; Emmanuel Mignot; Giuseppe Plazzi
Journal: Sleep Date: 2015-08-01 Impact factor: 5.849

Review 3. Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.

Authors: Lucie Barateau; Roland Liblau; Christelle Peyron; Yves Dauvilliers
Journal: CNS Drugs Date: 2017-10 Impact factor: 5.749

Review 4. Immunotherapy in Narcolepsy.

Authors: Maria Pia Giannoccaro; Giombattista Sallemi; Rocco Liguori; Giuseppe Plazzi; Fabio Pizza
Journal: Curr Treat Options Neurol Date: 2020-01-30 Impact factor: 3.598

Primary progressive narcolepsy type 1: the other side of the coin.

Review 1. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination.

2. Daytime continuous polysomnography predicts MSLT results in hypersomnias of central origin.

3. Hypocretin deficiency develops during onset of human narcolepsy with cataplexy.

4. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy.

5. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy.

6. Reduced number of hypocretin neurons in human narcolepsy.

Review 1. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.

2. Nocturnal Sleep Dynamics Identify Narcolepsy Type 1.

Review 3. Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.

Review 4. Immunotherapy in Narcolepsy.

Review 5. Sleep, cerebrospinal fluid, and the glymphatic system: A systematic review.

Review 6. The Medical and Economic Burden of Narcolepsy: Implications for Managed Care.

Review 7. The neurobiological basis of narcolepsy.

Review 8. Reviewing the Clinical Implications of Treating Narcolepsy as an Autoimmune Disorder.

Review 9. Treatment paradigms for cataplexy in narcolepsy: past, present, and future.

10. Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy.